Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|5|429-433

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.5, 2015-05, pp. : 429-433

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 9, 2015-09 ,pp. : 755-768

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term patient‐reported outcomes from an open‐label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or intolerant to prior therapy

CANCER, Vol. 124, Iss. 3, 2018-02 ,pp. : 587-595

John Wiley & Sons Inc

Access to resources Recommend Favorite

Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting

By Saleh Mansoor N. Haislip Sally Sharpe Joyce Hess Tamara Gilmore James Jackson James Sail Kavita R. Ericson Solveig G. Chen Lei

Current Medical Research and Opinion, Vol. 30, Iss. 4, 2014-04 ,pp. : 529-536

Informa Healthcare

Access to resources Recommend Favorite

Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

CANCER, Vol. 121, Iss. 21, 2015-11 ,pp. : 3894-3904

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Importance of Body Surface Area at Baseline and during Treatment in Chronic Myeloid Leukemia Patients Treated with Imatinib

Acta Haematologica, Vol. 134, Iss. 1, 2015-04 ,pp. : 57-58

Karger

Access to resources Recommend Favorite